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a  b  s  t  r  a  c  t
Male  and female  rats (26-day-old)  were  exposed  to 0.0, 0.4,  4  or 40  mg/kg  body  weight
silver  acetate  (AgAc)  in drinking  water  for 10  weeks  prior  to and during  mating.  Sperm-
positive  females  remained  within  their  dose  groups  and  were  exposed  to silver  acetate
during gestation  and  lactation.  At  postnatal  day  26,  the  effect  of  silver  ions  on  the  develop-
ing  F1  generation  rat  thymus  was  evaluated  at  the  transcriptional  level  using  whole-genome
microarrays.  Gene  expression  proﬁling  analyses  identiﬁed  a  dozen  differentially  expressed
genes (DEGs)  in  each  dose  group  using  a loose  criterion  of  fold  change  (FC)  >1.5  and  unad-
justed  p  <  0.05,  regardless  of whether  the analysis  was conducted  within  each  gender  group
or with  both  gender  groups  combined.  No  dose-dependent  effect  was  observed  on  the num-
ber of DEGs.  In  addition,  none  of these  genes  had  a  false  discovery  rate  (FDR)  <0.05  aftericroarray
hymus
evelopmental toxicity
correction  for multiple  testing.  These  results  in  combination  with  the  observation  that
thymus-to-body-weight  ratios  were  not  affected  and  no  histopathological  abnormalities
were  identiﬁed  indicate  that  in utero  exposure  to silver  ions  up to  26.0  mg/kg  (equivalent
to  40.0 mg/kg  silver  acetate)  did  not  have  an  adverse  effect  on  the  developing  thymus.
Published  by  Elsevier  Ireland  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-ND. Introduction
Silver has been used for centuries as a biocidal mate-
ial. In ancient time, silver was used to preserve water in
he form of silver vessels or silver coins. Its medical use
as documented as early as 750 AD. Starting from the
Abbreviations: AGCC, Affymetrix GeneChip Command Console; AgAc,
ilver acetate; AgNP, silver nanoparticle; DEG, differentially expressed
ene; FC, fold change; FDR, false discovery rate; HCA, hierarchical cluster
nalysis; NOEL, no observed effect level; NK, natural killer; PCA, princi-
al  components analysis; RMA, robust multi-array average; SV, source of
ariance.
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seventeenth century, silver has been used as antiseptics in a
number of medical situations such as cholera, eye infection,
and burn wound [2]. The U.S. Food and Drug Administra-
tion (FDA) approved the use of charged silver solutions
(i.e. electrocolloidals) as antibacterial agents in the 1920s.
The application of silver was further expanded during the
second half of the twentieth century as a disinfectant in
conjunction with hydrogen peroxide.
Today, silver-containing products are used in a wide
range of healthcare, food industry, and domiciliary appli-
cations and are commonly found in hard surface materials
and textiles. In the food industry, silver-containing
compounds or their mixtures are widely applied onto food-
packaging materials, often in direct contact with the food.
Such an extensive use of silver raises concerns about its
safety, toxicity, and health risk. However, there is a paucity
icle under the CC BY-NC-ND license (http://creativecommons.org/
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of information on the toxicity of silver. It is well known that
ingesting large amount of silver preparations, which rarely
happens, results in argyria, manifested by an irreversible
gray to blue-black coloring of the skin due to subder-
mal  silver deposit [11]. Also, the use of ionic silver and
silver derivatives for treatment and prevention of infec-
tion of burn wounds or skin grafting has been associated
with a number of side effects such as cytotoxicity, staining,
methaemoglobinaemia and electrolyte disturbance, longer
slough separation time, retardation of wound healing, and
the possible inactivation of enzyme debriding agents [4].
The free silver ion (Ag+) is the most toxic species of silver.
Toxicity testing in fathead minnow (Pimephales promelas)
showed that free silver ion was about 15,000 and 300 times
more acutely toxic than silver sulﬁde and silver chloride
complexes, respectively, which are the major forms of sil-
ver in the environment [9]. However, the toxic effect of
long-term exposure to low concentrations of silver has not
been well studied.
There is a potential risk for the developing fetus
when pregnant women are exposed to silver products. A
case–control epidemiology study was conducted by [1]
among women who delivered infants from 1977 to 1980
in a Massachusetts hospital. Trace element levels of pub-
lic water were analyzed from the communities in which
the women resided during pregnancy. The relationship
between community drinking water quality and the occur-
rence of late adverse pregnancy outcomes was examined.
After adjustment for confounding factors, the results sug-
gested some association between maternal exposures to
0.001 mg/L of silver in the drinking water (1/100 of the
EPA standard) and some increase in fetal developmental
anomalies (ear, face, and neck). As the authors recognized,
there are inferential limitations to epidemiologic studies
and further research is needed to explore these ﬁndings.
The U.S. FDA evaluated data available on the use of silver
mixtures as antimicrobial agents in food contact polymers
and suspected that in utero exposure to silver may  have an
adverse effect on the immune system of the developing ani-
mal. A comprehensive study for risk assessment has been
conducted in our group using a rat model and conventional
toxicological and/or pathological endpoints to conﬁrm that
the previously observed adverse effects are due to silver ion
alone, and to deﬁne the no observed effect level (NOEL) at
or below which the adverse effect does not occur [16].
Microarray technology has become a powerful tool to
explore the expression levels of thousands of genes or
even complete genomes after exposure to toxicants and
has thus found wide applications in toxicological research
[15]. Toxicogenomics, deﬁned as the “global analysis of
gene expression in target cells or tissues in response
to a toxicant,” has emerged as a promising approach to
evaluate mechanisms of action in toxicological models
[5]. Information on the global gene expression proﬁle
may  provide clues to understanding biological actions of
toxic substances at the molecular, cellular, tissue, and
individual animal levels. Tissue-speciﬁc gene expression
proﬁles can provide a basis for understanding tissue func-
tion, enabling molecular characterization of differences
between normal and diseased tissue. Toxicogenomics
also provides opportunities for improvements in toxicityrts 2 (2015) 341–350
screening and risk assessment such as the development
of new predictive models for identifying human health
hazards and the identiﬁcation of more precise molecular
biomarkers of exposure [12]. In this application, toxi-
cogenomic approaches usually are more sensitive than
conventional toxicological endpoint assays and can assess
toxic responses at low doses and at the very onset.
As a component of the comprehensive research [16],
the current study used a toxicogenomic approach to study
the effect of silver ions on the developing thymus at the
transcriptional level by using whole-genome microarrays
to study global gene expression changes in rat thymus of F1
generation offspring from dams exposed to different levels
of silver ion. In the last years, some dozen reports appeared
in the literature using toxicogenomics approach to study
silver toxicity; however, the majority of these studies were
on silver nanoparticles (AgNPs). Only a few evaluated sil-
ver ion toxicity either in a crustacean model [13], an in vitro
ﬁsh model [20], or in bacteria [21]. Silver ions and AgNPs
exerted toxicity through different mechanisms; the latter
was  affected by several other factors other than silver ion
itself, including surface coating and particle size [13]. To
our knowledge, this study represents the ﬁrst evaluation
of silver ion toxicity using toxicogenomics approach in a
mammalian model.
2. Materials and methods
2.1. Experimental design
Thymus tissues were obtained from 5 male and 5 female
F1 generation rat pups on postnatal day 26 in each treat-
ment group that were randomly selected from the animals
evaluated in [16]. In brief, 28-day-old male and female
CD IGS VAF/+ rats were exposed ad libidum to Hydro-
System water containing 0 (control), 0.4, 4.0, or 40.0 mg/kg
body weight silver acetate for 10 weeks prior to mating
and during the 2–3 week mating period. Sperm-positive
females remained within their dose groups and were fur-
ther exposed to silver acetate throughout the gestation and
lactation periods. Pups were weaned on lactation day 21
and euthanized for tissue collection on day 26. To minimize
potential litter effect, no more than one pup was  randomly
selected from each litter within a treatment group.
2.2. Tissue collection, RNA isolation, and quality
assurance
Thymus from each pup was collected and snap-frozen
in liquid N2 with 5 min  after dissection. The samples were
kept in a −80 ◦C freezer until processing for total RNA
extraction. Thymus was disrupted using the TissueLyser
(Qiagen, Valencia, CA) in the QIAzol Lysis Reagent (Qiagen)
and total RNA was isolated on the EZ1 Advanced XL (Qia-
gen) automated RNA puriﬁcation instrument using the EZ1
RNA Universal Tissue Kit (Qiagen) following the manufac-
turer’s protocol, including an on-column DNase digestion.
RNA concentration and purity (260/280 ratio) were mea-
sured with the NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE). Integrity of
RNA samples was assessed by the Agilent 2100 Bioanalyzer
gy Reports 2 (2015) 341–350 343
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Fig. 1. Principal component analysis based on all probe sets in the array
to  cluster samples based on their similarities or dissimilarities in global
gene expression level. The shape of each sample represents gender with
male samples as cubes and females as balls. The color represents different
treatment groups: grey, group 1 (control); green, group 2 (0.4 mg/kg);
blue, group 3 (4.0 mg/kg); red, group 4 (40.0 mg/kg). The three axes PC1,
PC2, and PC3 represent the ﬁrst three principal components identiﬁed
by the analysis. The percentage contribution of each component to the
overall source of variation is included in the parentheses following eachX. Gao et al. / Toxicolo
Santa Clara, CA) with the RNA 6000 Nano Reagent Kit from
he same manufacturer.
.3. Microarray experiment
The total RNA samples were preprocessed for hybridiza-
ion to GeneChip Rat Genome 230 2.0 Array (Affymetrix,
anta Clara, CA) using the Affymetrix GeneChip 3′ IVT
xpress Kit following the manufacturer’s protocol. In brief,
.1 g of total RNA was used to generate ﬁrst-strand cDNA
sing reverse transcriptase and a T7-linked oligo(dT)
rimer. After second-strand synthesis, the double-
tranded cDNA was then used for in vitro transcription with
iotinylated UTP and CTP to amplify the product, referred
o as cRNA ampliﬁcation. Subsequent hybridization,
ash, and staining were carried out using the Affymetrix
eneChip Hybridization, Wash, and Stain Kit and the man-
facturer’s protocols were followed. Brieﬂy, biotinylated
arget cRNA was  fragmented using heat and Mg2+ to sizes of
5–200 bp. Each fragmented cRNA target sample (approxi-
ately 12.5 g) was individually hybridized to a GeneChip
at Genome 230 2.0 Array at 45 ◦C for 16 h in Affymetrix
eneChip Hybridization Oven 645. After hybridization, the
rray chips were stained and washed using an Affymetrix
luidics Station 450. The chips were then scanned on
ffymetrix GeneChip Scanner 3000 7G and the image
.DAT) ﬁles were preprocessed using the Affymetrix
eneChip Command Console (AGCC) software v.3.2 to
enerate cell intensity (.CEL) ﬁles. The Rat Genome 230 2.0
rray comprises of over 31,000 probe sets representing
pproximately 28,700 well-substantiated rat genes. Prior
o data analysis, all arrays referred to in this study were
ssessed for data quality using the Affymetrix Expression
onsole software v.1.2 and all quality assessment metrics
including spike-in controls during target preparation and
ybridization) were found within boundaries.
.4. Data processing and statistical analysis
Data analysis was carried out primarily using the
.S. FDA’s ArrayTrack software system [17,18]. The val-
es of individual probes belonging to one probe set in
CEL ﬁles were summarized using the robust multi-array
verage (RMA) algorithm [8] embedded in ArrayTrack,
hich comprises of convolution background correction,
uantile normalization, and median polish summarization.
ormalized data for all samples were then analyzed by
nsupervised principal component analysis (PCA) [14] and
ierarchical cluster analysis (HCA) [3], both embedded in
rrayTrack, to identify patterns in the dataset and highlight
imilarities and differences among the samples. Subse-
uently, differentially expressed genes were selected using
ne-way analysis of variance (ANOVA) based on Welch’s
-test. To improve moderated t-statistics, a gene-ﬁltering
rocedure, namely I/NI-calls [6], was applied before the
elch’s t-test to exclude non-informative genes. For eachomparison between two experimental groups, the fold
hange (FC) of every annotated gene, together with their
orresponding p-value, was used for selection of differen-
ially expressed genes with cutoffs of p < 0.05 and FC > 1.5.component name. The ﬁrst principal component (PC1), which separates
the  samples into two gender clusters, has the largest variance (13.328),
followed by PC2 (10.144) and PC3 (4.839).
3. Results
3.1. Thymus and body weights
Table 1 summarizes the effects of silver acetate on rat
thymus and body weights in the subset of F1 generation
pups used in this study (the full animal dataset was  pre-
viously reported by [16]). Despite some decreases in the
mean thymus and body weights in the higher dosing groups
(4.0 and 40.0 mg/kg) compared with the control animals,
thymus/body weight ratios were similar in all groups. No
statistically signiﬁcant effects were seen in any group.
3.2. Global gene expression proﬁling
Unsupervised data exploration by principal compo-
nents analysis (PCA) was  ﬁrst conducted to identify major
effects inﬂuencing the expression values in the experi-
ment and to cluster samples based on their similarities or
dissimilarities in global gene expression level. As shown
in Fig. 1, overall the samples were separated by gender
into two major clusters. With each gender cluster, sam-
ples of different treatment groups were mixed with no
discrete boundaries between different groups, suggesting
treatment by silver acetate had little effect on global gene
expression level. Results of hierarchical cluster analysis
(HCA) (Fig. 2) are consistent with the PCA results. The sam-
ples were clustered by gender into two major branches;
344 X. Gao et al. / Toxicology Reports 2 (2015) 341–350
Table 1
Summary of thymus and body weights and their ratios.
Thymus Weight (mg)a Body Weight (g) Thymus/Body Ratio (mg/g)
Group 1 (Control) Male (5)b 302.9 ± 50.3 86.3 ± 4.8 3.5 ± 0.5
Female (5) 332.5 ± 14.3 81.5 ± 3.3 4.1 ± 0.3
All  (10) 317.7 ± 38.2 83.9 ± 4.6 3.8 ± 0.5
Group 2 (0.4 mg/kg) Male (5) 307.1 ± 62.2 86.7 ± 7.2 3.5 ± 0.6
Female (5) 343.9 ± 95.7 81.3 ± 12.1 4.2 ± 0.7
All  (10) 325.5 ± 78.5 84.0 ± 9.8 3.9 ± 0.7
Group 3 (4.0 mg/kg) Male (5) 304.9 ± 45.4 78.2 ± 4.2* 3.9 ± 0.7
Female (5) 280.5 ± 29.6** 74.1 ± 5.2* 3.8 ± 0.4
All  (10) 292.7 ± 38.3 76.1 ± 5.0** 3.9 ± 0.5
Group 4 (40.0 mg/kg) Male (5) 273.1 ± 54.8 76.7 ± 7.9* 3.5 ± 0.4
Female (5) 262.4 ± 58.6* 71.2 ± 8.2* 3.7 ± 0.7
All  (10) 267.7 ± 53.8* 74.0 ± 8.1** 3.6 ± 0.6
a Thymus was weighed after frozen in liquid nitrogen.
ose andb The number in parentheses indicates the number of animals in each d
* Signiﬁcant at p < 0.05.
** Signiﬁcant at p < 0.01.
within each gender cluster, however, the samples were
not clustered into different treatment groups. Instead, the
samples formed branches with no apparent relationships.
3.3. Differential gene expression in treatment groups
Differences in gene expression between the treatment
groups and the control were assessed using one-way anal-
ysis of variance (ANOVA). Since each gender had a distinct
pattern in global gene expression (Figs. 1 and 2), the anal-
ysis was conducted either separately for female and male
animals, or with all animals in the same dose group.
Fig. 2. Hierarchical cluster analysis based on all probe sets in the array to clus
expression level. The clustering was performed through Ward’s minimum varianc
coded  as shown in the scheme at the upper right corner. The tree on the right of 
the  top of the image shows clusters of samples. The naming of the samples follo
fourth  female pup in group 2. The branches in a tree contain similar samples or g sex group.
Consistent with the results from PCA and HCA
(Figs. 1 and 2), one-way ANOVA using Welch’s t-test also
indicated treatment by silver acetate had little effect on
gene expression. Using a stringent criterion of Bonferroni-
adjusted p < 0.05, the analysis revealed no differentially
expressed genes (DEGs) from all treatment groups (vs. con-
trols), whether the analysis was conducted within each
gender group or with both gender groups combined. When
a less stringent criterion (p-value not adjusted for multiple
testing, i.e., unadjusted p < 0.05) was used for the selection
of DEGs, a number of signiﬁcant genes with fold change
(FC) >1.5 were identiﬁed in each dose group (Tables 2–4).
Treatment with 0.4 mg/kg of silver acetate resulted in 16,
ter samples based on their similarities or dissimilarities in global gene
e linkage on normalized expression data which are in log2 scale and color
the image shows clusters of genes (names not shown), while the tree on
ws “group name-gender-replicate”; for example, “G2-F-4” refers to the
enes.
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Table  2
Differentially expressed genes in the groups treated with 0.4 mg/kg of silver.a
Gene ID GeneBank Acc. # Gene name Description FCb p FDRc
Female (16)
1369113 at NM 019282 Grem1 Gremlin 1 0.67 0.036 0.609
1374474 at BE099085 Cpne8 Copine VIII (predicted) 0.59 0.008 0.572
1378518 at BF394458 Ewsr1 Regulated endocrine-speciﬁc protein 18 0.53 0.010 0.572
1379547 at AA964652 0.27 0.014 0.590
1380559 at AI030465 Zic family member 2 (odd-paired homolog,
Drosophila) (predicted)
2.73 0.000 0.415
1381670 at BF412681 1.82 0.047 0.638
1385098 at AW526343 Sortilin-related VPS10 domain containing
receptor 3 (predicted)
0.63 0.008 0.571
1388985 at AI012869 LOC100361467 Coﬁlin 2, muscle (predicted) 0.63 0.024 0.607
1389649 at AI411897 0.66 0.009 0.572
1391830 at AI059204 Cpne8 Copine VIII (predicted) 0.59 0.006 0.563
1395221 at AA892908 Snx13 Sorting nexin 13 (predicted) 0.66 0.043 0.626
1395888 at BF559498 1.61 0.023 0.607
1396019 at BF419464 Coiled-coil-helix-coiled-coil-helix domain
containing 5 (predicted)
1.61 0.036 0.609
1396931 at AI137091 1.68 0.042 0.622
1397064 at BE114456 1.56 0.034 0.609
1397730 at C06959 RGD1307235 Similar to RIKEN cDNA 2310035C23
(predicted)
0.65 0.001 0.560
Male  (16)
1368487 at NM 021696 Serpinb2 Serine (or cysteine) peptidase inhibitor, clade
B,  member 2
1.56 0.034 0.376
1370382 at BI279526 RT1-Db1 RT1 class II, locus Db1 2.20 0.014 0.351
1375562 at BF408460 Similar to [Mouse primary response gene B94
mRNA, 3end.], gene product
0.66 0.003 0.306
1375758 at BF404935 0.48 0.048 0.397
1376780 at AI172311 Fam103a1 Family with sequence similarity 103, member
A1
0.39 0.025 0.364
1379435 at AI599463 Dguok Deoxyguanosine kinase (predicted) 4.51 0.022 0.354
1385240 at AW523099 Wdr33 WD repeat domain 33 (predicted) 0.64 0.046 0.395
1388236 x at M24026 RT1-CE12 RT1 class I, CE12 0.63 0.048 0.397
1388272 at AI411947 LOC100363606 Immunoglobulin heavy chain 1a (serum IgG2a) 2.18 0.034 0.375
1391544 at BI285941 Similar to adiponutrin 0.55 0.047 0.396
1392118 at BE099845 0.66 0.006 0.331
1392854 at BE116127 RGD1564560 Similar to RCK (predicted) 1.75 0.011 0.349
1392894 at AI716194 Fgl2 Fibrinogen-like 2 1.70 0.009 0.349
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.61 0.032 0.372
1397064 at BE114456 1.65 0.003 0.306
1398533 at BE105837 Cyﬁp2 Cytoplasmic FMR1 interacting protein 2
(predicted)
0.58 0.012 0.351
All  (15)
1367739 at NM 012786 Cox8b cytochrome c oxidase, subunit 8B 0.61 0.044 0.924
1371363 at BI277042 Gpd1 Glycerol-3-phosphate dehydrogenase 1
(soluble)
0.55 0.039 0.924
1371400 at AI169092 Thrsp Thyroid hormone responsive protein 0.55 0.045 0.924
1375758 at BF404935 0.61 0.016 0.924
1378518 at BF394458 Ewsr1 Regulated endocrine-speciﬁc protein 18 0.66 0.008 0.924
1379547 at AA964652 0.37 0.005 0.924
1381670 at BF412681 1.66 0.017 0.924
1382849 at AA893195 4.15 0.008 0.924
1385380 at AI044983 0.65 0.009 0.924
1386911 at NM 012505 Atp1a2 ATPase, Na+/K+ transporting, alpha 2
polypeptide
0.60 0.030 0.924
1388272 at AI411947 LOC100363606 Immunoglobulin heavy chain 1a (serum IgG2a) 1.78 0.012 0.924
1391544 at BI285941 Similar to adiponutrin 0.63 0.013 0.924
1393738 s at AI136864 Mfhas1 Malignant ﬁbrous histiocytoma ampliﬁed
sequence 1 (predicted)
0.66 0.039 0.924
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.67 0.003 0.924
1397064 at BE114456 1.60 0.000 0.924
a The analysis was conducted within each gender group (“Female” or “Male”) or with both gender groups combined (“All”). The number of signiﬁcant
genes  in each gender group is included in parentheses following the gender name.
b Fold changes relative to the control group.
c False discovery rate, which is the probability of having false tests among all the signiﬁcant tests. For example, an FDR of 0.05 indicates that 5% of the
signiﬁcant genes may have been identiﬁed by chance (i.e., the false-positives).
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Table 3
Differentially expressed genes in the groups treated with 4.0 mg/kg of silver.a
Gene ID GeneBank Acc. # Gene name Description FCb p FDRc
Female (13)
1368337 at NM 012794 Glycam1 Glycosylation-dependent cell adhesion
molecule 1
0.50 0.012 0.986
1369342 at NM 052803 Atp7a ATPase, Cu2+ transporting, alpha polypeptide 2.84 0.010 0.986
1372264 at BI277460 Pck1 Phosphoenolpyruvate carboxykinase 1,
cytosolic
0.40 0.025 0.986
1381208 at BE104595 Hist3h2a Histone cluster 3, H2a 1.51 0.030 0.986
1381990 at AA963979 UDP-N-acetyl-alpha-d-
galactosamine:polypeptide
N-acetylgalactosaminyltransferase 1
0.66 0.006 0.986
1382849 at AA893195 4.12 0.049 0.986
1383242 a at BF561222 0.56 0.022 0.986
1384372 at BF545278 Neural precursor cell-expressed,
developmentally down-regulated gene 4A
1.52 0.048 0.986
1388985 at AI012869 LOC100361467 Coﬁlin 2, muscle (predicted) 0.62 0.012 0.986
1392189 at BE105136 Rfx4 Regulatory factor X, 4 (inﬂuences HLA class II
expression)
2.08 0.026 0.986
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.44 0.022 0.986
1397463 at BE105818 Rab14 RAB14, member RAS oncogene family 0.64 0.030 0.986
1397730 at C06959 RGD1307235 Similar to RIKEN cDNA 2310035C23
(predicted)
0.56 0.001 0.986
Male  (9)
1372927 at AA891839 Mrpl50 Mitochondrial ribosomal protein L50
(predicted)
0.62 0.001 0.994
1380773 at BI288767 6-Phosphogluconolactonase (predicted) 1.52 0.014 0.994
1381858 at BM387283 Trim14 Tripartite motif protein 14 (predicted) 0.67 0.013 0.994
1384136 at BI291045 Osbpl3 Oxysterol binding protein-like 3 0.66 0.044 0.994
1385635 at AI029143 Cd5l CD5 antigen-like 2.17 0.022 0.994
1392012 at BE100353 LOC686567 0.61 0.043 0.994
1392894 at AI716194 Fgl2 Fibrinogen-like 2 1.52 0.045 0.994
1393738 s at AI136864 Mfhas1 Malignant ﬁbrous histiocytoma-ampliﬁed
sequence 1 (predicted)
0.53 0.033 0.994
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.46 0.038 0.994
All  (9)
1369342 at NM 052803 Atp7a ATPase, Cu2+ transporting, alpha polypeptide 1.97 0.035 0.909
1370312 at M88469 Spon1 Spondin 1 0.65 0.038 0.909
1379547 at AA964652 0.46 0.028 0.909
1382849 at AA893195 3.10 0.023 0.909
1383242 a at BF561222 0.66 0.021 0.909
1385635 at AI029143 Cd5l CD5 antigen-like 1.74 0.021 0.909
1392012 at BE100353 LOC686567 0.65 0.009 0.909
1392189 at BE105136 Rfx4 Regulatory factor X, 4 (inﬂuences HLA class II
expression)
1.82 0.020 0.909
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.45 0.001 0.896
a The analysis was  conducted within each gender group (“Female” or “Male”) or with both gender groups combined (“All”). The number of signiﬁcant
genes  in each gender group is included in parentheses following the gender name.
ong all t
ives).b Fold changes relative to the control group.
c False discovery rate, which is the probability of having false tests am
signiﬁcant genes may  have been identiﬁed by chance (i.e., the false-posit
16, and 15 DEGs for female, male, and combined groups. At
4.0 mg/kg, the numbers of DEGs were 13, 9, and 9 respec-
tively; and at 40.0 mg/kg, the numbers were 14, 12, and
10.
Although the numbers of DEGs did not show dose
dependency, the false discovery rate (FDR), which is a
statistic (p-value) moderately adjusted for multiple test-
ing, were markedly different among different dose groups,
and in some cases between different gender groups with
the same dose group as well. Remarkably, six probe sets in
the male group of the highest dose group (40.0 mg/kg) had
an FDR < 0.1 (highlighted in Table 4). Among these probe
sets, two are serine/cysteine peptidase inhibitor, namely
Serpinb2 and Serpinb3a, one is predicted to be similarhe signiﬁcant tests. For example, an FDR of 0.05 indicates that 5% of the
to the regulator of K+ conductance (RCK), another one is
an RNA-speciﬁc adenosine deaminase and the remaining
two  are actin binding protein and RNA binding protein,
respectively. The heat map  shown in Fig. 3 illustrates the
differential expression of these genes in the high-dose
group (40.0 mg/kg) compared with the control group.
The numbers of DEGs for each treatment or gender
group as well as the numbers of overlapping genes are
plotted in the Venn diagrams shown in Fig. 4. Within
the same dose group (Fig. 4A), it is apparent that differ-
ent gender groups shared no or very small numbers of
genes compared to the total number of changed genes in
each gender group, suggesting the gene expression changes
were gender-dependent. Similarly, different dose groups
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Table  4
Differentially expressed genes in the groups treated with 40.0 mg/kg of silver.a
Gene ID GeneBank Acc. # Gene name Description FCb p FDRc
Female (14)
1368826 at NM 012531 Comt Catechol-O-methyltransferase 0.32 0.030 0.998
1369342 at NM 052803 Atp7a ATPase, Cu2+ transporting, alpha polypeptide 2.13 0.021 0.998
1378346 at AI385237 Similar to IQ motif and WD repeats 1 0.62 0.021 0.998
1379170 at BF393059 0.66 0.012 0.998
1381613 at BI290213 0.39 0.020 0.998
1382597 at BF288069 Formin binding protein 3 (predicted) 0.63 0.001 0.998
1383187 a at AA944136 Bol, boule-like (Drosophila) (predicted) 0.59 0.030 0.998
1383242 a at BF561222 0.50 0.016 0.998
1383598 at AI136294 Wdr91 WD repeat domain 91 1.55 0.013 0.998
1384067 at BF288361 0.40 0.024 0.998
1384126 a at AW917217 Cytoskeleton-associated protein 2 (predicted) 0.60 0.004 0.998
1384136 at BI291045 Osbpl3 Oxysterol binding protein-like 3 1.90 0.011 0.998
1388985 at AI012869 LOC100361467 Coﬁlin 2, muscle (predicted) 0.53 0.027 0.998
1392591 at AI170983 MGC125002 Similar to RIKEN cDNA 5830433M19 0.65 0.002 0.998
Male  (12)
1368487 at* NM 021696 Serpinb2 Serine/cysteine peptidase inhibitor, clade B,
member 2
1.64 0.002 0.073
1370371 a at U23056 Ceacam1///Ceacam10 CEA-related cell adhesion molecule 10 0.45 0.014 0.130
1372725 at AI411594 Plscr2 Phospholipid scramblase 2 1.57 0.047 0.208
1378738 at BE097574 Kcnab1 Potassium voltage-gated channel,
shaker-related subfamily, beta member 1
1.67 0.049 0.213
1378866 at* BF401176 Actin-binding LIM protein 1 1.85 0.003 0.079
1381839 at AA957129 Similar to hypothetical protein FLJ13855
(predicted)
0.60 0.027 0.161
1383163 at AA817898 Igj Immunoglobulin joining chain 1.52 0.039 0.191
1392854 at* BE116127 RGD1564560 Similar to RCK (predicted) 2.02 0.006 0.094
1393738 s at AI136864 Mfhas1 Malignant ﬁbrous histiocytoma ampliﬁed
sequence 1 (predicted)
0.54 0.031 0.174
1394585 at* BE116089 Adenosine deaminase, RNA-speciﬁc 0.55 0.000 0.052
1397212 at* AW534279 Spermatid perinuclear RNA binding protein 0.64 0.001 0.064
1397463 at BE105818 Rab14 RAB14, member RAS oncogene family 0.50 0.017 0.140
1397635 at* BM390325 Serpinb3a Serine (or cysteine) peptidase inhibitor, clade B
(ovalbumin), member 3A
1.83 0.004 0.080
All  (10)
1369342 at NM 052803 Atp7a ATPase, Cu2+ transporting, alpha polypeptide 2.22 0.007 0.228
1370371 a at U23056 Ceacam1///Ceacam10 CEA-related cell adhesion molecule 10 0.49 0.002 0.162
1381613 at BI290213 0.50 0.005 0.204
1383242 a at BF561222 0.60 0.022 0.288
1384067 at BF288361 0.48 0.005 0.204
1384393 at BE120370 Cln3p 1.63 0.034 0.321
1388985 at AI012869 LOC100361467 Coﬁlin 2, muscle (predicted) 0.61 0.005 0.204
1393795 at BG377397 Zeb2 Zinc ﬁnger E-box binding homeobox 2 0.61 0.012 0.256
1394671 at AI454769 Glucosamine (N-acetyl)-6-sulfatase (predicted) 0.60 0.014 0.263
1397463 at BE105818 Rab14 RAB14, member RAS oncogene family 0.61 0.003 0.171
a The analysis was conducted within each gender group (“Female” or “Male”) or with both gender groups combined (“All”). The number of signiﬁcant
genes  in each gender group is included in parentheses following the gender name.
b Fold changes relative to the control group.
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ic False discovery rate, which is the probability of having false tests am
igniﬁcant genes may have been identiﬁed by chance (i.e., the false-posit
* Genes with FDR < 0.1.
ithin the same gender group also had very few overlapped
enes compared to the total number of changed genes
n each dose group (Fig. 4B), suggesting the gene expres-
ion changes were also dose-dependent. However, source
f variance (SV) plot from two-way ANOVA on dose and
ender (Fig. 5) indicated that gender had a much greater
ontribution than dose to the gene expression changes.
. DiscussionWith the increasing application of silver-containing
ompounds as antimicrobial agents in the food industry,
t is imperative to study their safety, toxicity, and healthhe signiﬁcant tests. For example, an FDR of 0.05 indicates that 5% of the
effect. The U.S. FDA evaluated data available on the use
of silver mixtures as antimicrobial agents in food contact
polymers and suspected that in utero exposure to silver
may  have an adverse effect on the immune system of the
developing animal. A comprehensive study for risk assess-
ment has been conducted in our group using a rat model
and conventional toxicological and/or pathological end-
points to conﬁrm that the previously observed adverse
effects are due to silver ion alone and to deﬁne the NOEL
[16].
As a component of the comprehensive research, the
present study used a toxicogenomic approach to study
the effect of silver ions on the developing thymus at the
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Fig. 3. Heat map  showing the differential expression of some genes with
FDR  < 0.1 in males of the high dose group (40.0 mg/kg, G4) compared with
the  control group (G1). The data are normalized signal intensity value in
Fig. 5. Source of variance (SV) plot from two-way ANOVAs showing thelog2 scale and color coded as shown in the scheme at the upper right cor-
ner. The naming of the samples follows “group name-gender-replicate”;
for  example, “G4-M-1” refers to the ﬁrst male pup in group 4.
transcriptional level. Global gene expression proﬁle in rat
thymus of F1 generation pups at postnatal day 26 follow-
ing maternal exposure to silver acetate at 0, 0.4, 4.0, or
40.0 mg/kg in drinking water are reported here. Unsuper-
vised data exploration by PCA (Fig. 1) and HCA (Fig. 2)
revealed that the samples were separated by gender into
two major clusters. Within each gender group, however,
no distinct expression patterns were identiﬁed for differ-
ent dose groups, suggesting treatment by silver acetate had
little effect on global gene expression. Consistently, one-
way ANOVA identiﬁed only about a dozen DEGs in each
dose group with FC > 1.5 and unadjusted p < 0.05, and none
of these genes had an FDR <0.05 (Tables 2–4). Six genes
had an FDR < 0.1 in the males of the highest treatment
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Fig. 4. Venn diagrams showing overlap of differentially expressed genes (DEGs) b
different dose groups in the same gender group (B). The total number of DEGs in contribution from gender, dose, their interaction (gender × dose), and
error.
group (Table 4); however, visual inspection of the heat
map  suggests these genes are likely false-positives (Fig. 4).
Taken together, these results indicate silver acetate up to
40.0 mg/kg did not affect gene expression in the developing
thymus.
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In the large-scale study, no histopathological abnormal-
ties in thymus were identiﬁed in the F1 generation pups in
ny of the dosing groups [16]. Combined with the observa-
ion that thymus-to-body-weight ratios were not affected
Table 1), the current study suggests that in utero exposure
o silver ions up to 26.0 mg/kg (equivalent to 40.0 mg/kg
ilver acetate) did not have an adverse effect on the devel-
ping thymus.
A parallel component study [19] on natural killer (NK)
ctivity and mitogen-induced lymphocyte proliferation in
he spleen of the F1 generation pups has found that mater-
al exposure to 4.0 and 40.0 mg/kg silver acetate resulted
n reduced T-cell development and cell-mediated immune
unctions in 4-day pups, and reduced TCR+ cells and cell-
ediated immune functions in 26-day-old pups, although
xposure to low concentration of silver acetate (0.4 mg/kg)
as slight beneﬁcial effect on NK activity in 26-day pups.
n contrast, no effect was observed on thymic lympho-
ytes. Hultman et al. [7] found that Brown Norway (BN) rats
xposed to silver in dental amalgam restorations had sig-
iﬁcantly increased metal (including silver) concentrations
n tissue in the order kidney > spleen > cerebrum occipital
obe > cerebellum > liver > thymus. For example, mercury
oncentration in spleen is more than 30-fold higher than
hat in thymus. Silver accumulation may  follow the same
attern as mercury. This may  partly explain the results
f [19] that silver acetate had a signiﬁcant impact on the
plenic but not thymic immune system and may  also help
o explain the ﬁndings of the current study that silver
cetate had not signiﬁcant effect on thymic gene expres-
ion.
It should be noted that silver ions may  exert systemic
ffects on the developing pups that are not evident in
peciﬁc organs. McIntyre et al. [10] reported that a 12-
onth infant overdosed with colloidal silver in the form
f dietary supplements manifested global developmental
etardation, although this case was complicated by mal-
utrition. In the comprehensive study [16], higher runt
umbers and low average body weights were observed in
ups following maternal exposure to silver acetate at high
oncentrations (4.0 and 40.0 mg/kg). In addition, prenatal
eath rate of newborns was also higher in dams exposed
o high concentrations (4.0 and 40.0 mg/kg) of silver
cetate.
. Conclusions
In the present study, we used a toxicogenomic approach
o study the effect of silver ions on the developing thy-
us  by measuring transcriptome changes in rat thymus
f F1 generation pups following maternal exposure to sil-
er acetate. Gene expression proﬁling analyses indicate
hat silver acetate up to 40.0 mg/kg did not affect gene
xpression in the developing thymus. Combined with the
bservation that thymus-to-body-weight ratios were not
ffected, and no histopathological abnormalities in thymus
ere identiﬁed in the pups, the current study suggests that
n utero exposure to silver ions up to 26.0 mg/kg (equiva-
ent to 40.0 mg/kg silver acetate) did not have an adverse
ffect on the developing thymus.
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